CA9 and neoplasm: Tumor and normal tissue uptake of [111In]In-DOTA-HE3-ZCAIX:2, [111In]In-DTPA-girentuximab-F(ab′)2 and [111In]In-DTPA-girentuximab was determined in both SCCNij153 (high CAIX expression) and SCCNij185 (low CAIX expression) human head and neck tumor xenografts at time points reported to be optimal for each construct.